Literature DB >> 25872610

The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers.

Bauke Schievink1, Dick de Zeeuw1, Hans-Henrik Parving2,3, Peter Rossing4, Hiddo Jan Lambers Heerspink1.   

Abstract

AIMS: Angiotensin receptor blockers (ARBs) are renoprotective and targeted to blood pressure. However, ARBs have multiple other (off-target) effects which may affect renal outcome. It is unknown whether on-target and off-target effects are congruent within individuals. If not, this variation in short term effects may have important implications for the prediction of individual long term renal outcomes. Our aim was to assess intra-individual variability in multiple parameters in response to ARBs in type 2 diabetes.
METHODS: Changes in systolic blood pressure (SBP), albuminuria, potassium, haemoglobin, cholesterol and uric acid after 6 months of losartan treatment were assessed in the RENAAL database. Improvement in predictive performance of renal outcomes (ESRD or doubling serum creatinine) for each individual using ARB-induced changes in all risk markers was assessed by the relative integrative discrimination index (RIDI).
RESULTS: SBP response showed high variability (mean -5.7 mmHg, 5(th) to 95(th) percentile -36.5 to +24.0 mmHg) between individuals. Changes in off-target parameters also showed high variability between individuals. No congruency was observed between responses to losartan in multiple parameters within individuals. Using individual responses in all risk markers significantly improved renal risk prediction (RIDI 30.4%, P < 0.01) compared with using only SBP changes. Results were successfully replicated in two independent trials with irbesartan, IDNT and IRMA-2.
CONCLUSIONS: In this post hoc analysis we showed that ARBs have multiple off-target effects which vary between and within individuals. Combining all ARB-induced responses beyond SBP provides a more accurate prediction of who will benefit from ARB therapy. Prospective trials are required to validate these findings.
© 2015 The British Pharmacological Society.

Entities:  

Keywords:  angiotensin receptor blockers; personalized medicine; renal disease; type 2 diabetes

Mesh:

Substances:

Year:  2015        PMID: 25872610      PMCID: PMC4594704          DOI: 10.1111/bcp.12655

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  34 in total

1.  Biomarkers and personalized therapy in chronic kidney diseases.

Authors:  Francesco Paolo Schena
Journal:  Expert Opin Investig Drugs       Date:  2014-05-26       Impact factor: 6.206

2.  Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy.

Authors:  H Bos; S Andersen; P Rossing; D De Zeeuw; H H Parving; P E De Jong; G Navis
Journal:  Kidney Int Suppl       Date:  2000-04       Impact factor: 10.545

3.  A novel approach for establishing cardiovascular drug efficacy.

Authors:  Hiddo J Lambers Heerspink; Diederick E Grobbee; Dick de Zeeuw
Journal:  Nat Rev Drug Discov       Date:  2014-11-14       Impact factor: 84.694

4.  Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials.

Authors:  Frank A Holtkamp; Dick de Zeeuw; Pieter A de Graeff; Gozewijn D Laverman; Tom Berl; Giuseppe Remuzzi; David Packham; Julia B Lewis; Hans-Henrik Parving; Hiddo J Lambers Heerspink
Journal:  Eur Heart J       Date:  2011-03-18       Impact factor: 29.983

5.  Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus.

Authors:  Norman K Hollenberg; Hans-Henrik Parving; Giancarlo Viberti; Giuseppe Remuzzi; Susan Ritter; Steven Zelenkofske; Albert Kandra; William L Daley; Ricardo Rocha
Journal:  J Hypertens       Date:  2007-09       Impact factor: 4.844

6.  Development of a type 2 diabetes risk model from a panel of serum biomarkers from the Inter99 cohort.

Authors:  Janice A Kolberg; Torben Jørgensen; Robert W Gerwien; Sarah Hamren; Michael P McKenna; Edward Moler; Michael W Rowe; Mickey S Urdea; Xiaomei M Xu; Torben Hansen; Oluf Pedersen; Knut Borch-Johnsen
Journal:  Diabetes Care       Date:  2009-07       Impact factor: 19.112

7.  Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.

Authors:  Y Miao; D Dobre; H J Lambers Heerspink; B M Brenner; M E Cooper; H-H Parving; S Shahinfar; D Grobbee; D de Zeeuw
Journal:  Diabetologia       Date:  2010-09-30       Impact factor: 10.122

Review 8.  The evolving story of the RAAS in hypertension, diabetes and CV disease: moving from macrovascular to microvascular targets.

Authors:  Ulrike Muscha Steckelings; Franziska Rompe; Elena Kaschina; Thomas Unger
Journal:  Fundam Clin Pharmacol       Date:  2009-10-09       Impact factor: 2.748

9.  The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study.

Authors:  William F Keane; Barry M Brenner; Dick de Zeeuw; Jean-Pierre Grunfeld; Janet McGill; William E Mitch; Artur B Ribeiro; Shahnaz Shahinfar; Roger L Simpson; Steven M Snapinn; Robert Toto
Journal:  Kidney Int       Date:  2003-04       Impact factor: 10.612

10.  Joint analysis of multiple biomarkers for identifying type 2 diabetes in middle-aged and older Chinese: a cross-sectional study.

Authors:  Hongyu Wu; Zhijie Yu; Qibin Qi; Huaixing Li; Qi Sun; Xu Lin
Journal:  BMJ Open       Date:  2011-08-27       Impact factor: 2.692

View more
  19 in total

1.  Variability in response to albuminuria-lowering drugs: true or random?

Authors:  Sergei I Petrykiv; Dick de Zeeuw; Frederik Persson; Peter Rossing; Ron T Gansevoort; Gozewijn D Laverman; Hiddo J L Heerspink
Journal:  Br J Clin Pharmacol       Date:  2017-02-01       Impact factor: 4.335

2.  Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function.

Authors:  Sergei Petrykiv; C David Sjöström; Peter J Greasley; John Xu; Frederik Persson; Hiddo J L Heerspink
Journal:  Clin J Am Soc Nephrol       Date:  2017-03-16       Impact factor: 8.237

Review 3.  Precision Nephrology in Patients with Diabetes and Chronic Kidney Disease.

Authors:  Michele Provenzano; Federica Maritati; Chiara Abenavoli; Claudia Bini; Valeria Corradetti; Gaetano La Manna; Giorgia Comai
Journal:  Int J Mol Sci       Date:  2022-05-20       Impact factor: 6.208

4.  Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers.

Authors:  Bauke Schievink; Dick de Zeeuw; Paul A Smink; Dennis Andress; John J Brennan; Blai Coll; Ricardo Correa-Rotter; Fan Fan Hou; Donald Kohan; Dalane W Kitzman; Hirofumi Makino; Hans-Henrik Parving; Vlado Perkovic; Giuseppe Remuzzi; Sheldon Tobe; Robert Toto; Jarno Hoekman; Hiddo J Lambers Heerspink
Journal:  Eur J Prev Cardiol       Date:  2015-07-30       Impact factor: 7.804

5.  Early Proteinuria Lowering by Angiotensin-Converting Enzyme Inhibition Predicts Renal Survival in Children with CKD.

Authors:  Sophie M van den Belt; Hiddo J L Heerspink; Valentina Gracchi; Dick de Zeeuw; Elke Wühl; Franz Schaefer
Journal:  J Am Soc Nephrol       Date:  2018-06-21       Impact factor: 10.121

Review 6.  Pooled Analysis of Multiple Crossover Trials To Optimize Individual Therapy Response to Renin-Angiotensin-Aldosterone System Intervention.

Authors:  Sergei I Petrykiv; Gozewijn Dirk Laverman; Frederik Persson; Liffert Vogt; Peter Rossing; Martin H de Borst; Ronald T Gansevoort; Dick de Zeeuw; Hiddo J L Heerspink
Journal:  Clin J Am Soc Nephrol       Date:  2017-10-11       Impact factor: 8.237

7.  The effect of initiation of renin-angiotensin system inhibitors on haemoglobin: A national cohort study.

Authors:  George H B Greenhall; Kathryn E Mansfield; Dorothea Nitsch; Masao Iwagami; Clémence Leyrat; Rosalynd Johnston; Liam Smeeth; Laurie A Tomlinson
Journal:  Br J Clin Pharmacol       Date:  2020-07-05       Impact factor: 3.716

8.  Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers.

Authors:  H J L Heerspink; E Johnsson; I Gause-Nilsson; V A Cain; C D Sjöström
Journal:  Diabetes Obes Metab       Date:  2016-06       Impact factor: 6.577

9.  Serum metabolites predict response to angiotensin II receptor blockers in patients with diabetes mellitus.

Authors:  Michelle J Pena; Andreas Heinzel; Peter Rossing; Hans-Henrik Parving; Guido Dallmann; Kasper Rossing; Steen Andersen; Bernd Mayer; Hiddo J L Heerspink
Journal:  J Transl Med       Date:  2016-07-05       Impact factor: 5.531

Review 10.  Proteomics for prediction of disease progression and response to therapy in diabetic kidney disease.

Authors:  Michelle J Pena; Harald Mischak; Hiddo J L Heerspink
Journal:  Diabetologia       Date:  2016-06-25       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.